Angela Wiczek - Insulet Senior Communications
| PODD Stock | USD 330.84 2.67 0.80% |
Executive
Angela Wiczek is Senior Communications of Insulet
| Phone | 978 600 7000 |
| Web | https://www.insulet.com |
Insulet Management Efficiency
The company has return on total asset (ROA) of 0.0775 % which means that it generated a profit of $0.0775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1918 %, meaning that it created $0.1918 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Tom Fox | Tandem Diabetes Care | N/A | |
| Pankaj Tiwari | Penumbra | N/A | |
| Blair Tripodi | Masimo | 51 | |
| Jordan MD | Tandem Diabetes Care | N/A | |
| Donald Abbey | DexCom Inc | 58 | |
| Stacey Stewart | DexCom Inc | N/A | |
| Carlton Weatherby | Inspire Medical Systems | 40 | |
| Ivan Lubogo | Inspire Medical Systems | N/A | |
| Elizabeth Gasser | Tandem Diabetes Care | 49 | |
| Jason Mills | Penumbra | N/A | |
| Michael Brown | DexCom Inc | 55 | |
| Omar Ahmed | Masimo | N/A | |
| Ezgi Yagci | Inspire Medical Systems | N/A | |
| Matthew Dolan | DexCom Inc | 44 | |
| David Esq | Tandem Diabetes Care | 55 | |
| Ben Tompkins | Penumbra | N/A | |
| Susan Morrison | Tandem Diabetes Care | 46 | |
| Libba Sapitsky | Tandem Diabetes Care | N/A | |
| Mark Novara | Tandem Diabetes Care | 50 | |
| Martin Abrams | Inspire Medical Systems | N/A | |
| Eli Kammerman | Masimo | N/A | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0775 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
| Philip Hildale, Senior Care | ||
| Andrew Isaacson, Senior Development | ||
| Mark Field, Senior CTO | ||
| Laetitia Cousin, Quality Affairs | ||
| John Kapples, Senior Vice President General Counsel, Secretary | ||
| Carolyn Sleeth, Senior Manager | ||
| Wayde McMillan, CFO, Executive Vice President | ||
| Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
| Dan Manea, Senior Officer | ||
| James Hollingshead, CEO President | ||
| Bret Christensen, Chief Commercial Officer | ||
| June Lazaroff, Senior Relations | ||
| Deborah CPA, Vice Relations | ||
| Ashley McEvoy, President CEO | ||
| Lisa Davis, Senior Officer | ||
| Patricia Dolan, VP Secretary | ||
| Patrick Crannell, Senior Manager | ||
| Michael CPA, Advisor | ||
| Prem Singh, Senior Operations | ||
| John JD, Senior Counsel | ||
| Amit Guliani, Interim Engineering | ||
| Angela Wiczek, Senior Communications | ||
| Lauren Budden, Chief VP | ||
| Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
| Ana Chadwick, Executive CFO | ||
| Shacey Petrovic, Chief Commercial Officer | ||
| Trang Ly, Senior Officer |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0775 | ||||
| Profit Margin | 0.10 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 22.97 B | ||||
| Shares Outstanding | 70.39 M | ||||
| Shares Owned By Insiders | 0.26 % | ||||
| Shares Owned By Institutions | 99.74 % | ||||
| Number Of Shares Shorted | 1.62 M | ||||
| Price To Book | 15.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in national income and product accounts. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.